AMPK as a Potential Anticancer Target - Friend or Foe?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|15|2607-2618

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.15, 2014-05, pp. : 2607-2618

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Aryl Hydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe?

By  

Current Pharmaceutical Design, Vol. 8, Iss. 27, 2002-12 ,pp. : 2475-2490

Bentham Science Publishers

Access to resources Recommend Favorite

Update to: The Aryl Hydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe?

By  

Medicinal Chemistry Reviews - Online, Vol. 2, Iss. 2, 2005-01 ,pp. : 153-161

Bentham Science Publishers

Access to resources Recommend Favorite

Tungsten or Wolfram: Friend or Foe?

By  

Current Medicinal Chemistry, Vol. 25, Iss. 1, 2018-01 ,pp. : 65-74

Bentham Science Publishers

Access to resources Recommend Favorite

COX-2: Friend or Foe?

By  

Current Pharmaceutical Design, Vol. 13, Iss. 16, 2007-06 ,pp. : 1715-1721

Bentham Science Publishers

Access to resources Recommend Favorite

CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?

By  

Current Gene Therapy, Vol. 17, Iss. 6, 2018-03 ,pp. : 442-452

Bentham Science Publishers

Access to resources Recommend Favorite